心肝宝胶囊治疗慢性乙型肝炎肝纤维化临床研究

目的探讨心肝宝胶囊(虫草菌丝)治疗慢性乙型肝炎肝纤维化的疗效。方法 60例慢性乙型肝炎患者随机分为心肝宝胶囊组(40例)和对照组(20例),心肝宝胶囊组服用心肝宝胶囊,每次8粒,每日3次;对照组服用和络舒肝片,每次5粒,每日3次,两组均6个月为1疗程。检测两组患者治疗前后肝功能、血清纤维化4项指标和肝脏组织学等项目。结果心肝宝胶囊组治疗后血清ALT、AST水平,透明质酸(HA)、Ⅲ型前胶原(PC-Ⅲ)及层黏联蛋白(LN)含量较治疗前均降低,差异有统计学意义(P<0.05);对照组治疗后HA、LN含量较治疗前降低,差异有统计学意义(P<0.05)。心肝宝胶囊组共有21例(53%入组病例)完成了治疗前后2次肝活检,心肝宝胶囊可使81%(17/21)患者肝组织炎症活动度下降1级或以上,52%(11/21)患者纤维化分期下降1期或以上,33%(7/21)患者纤维化无变化。结论心肝宝胶囊具有改善肝功能、减轻肝组织炎症和抗肝纤维化作用。

Clinical Research of Xinganbao Capsule on the Treatment of Chronic Hepatitis B Liver Fibrosis

Objective To explore the effects of Xinganbao Capsule(Cordyceps Sinensis) on the chronic hepatitis B liver fibrosis.Methods Sixty patients with chronic hepatitis B were randomly assigned to the trail group(40 cases) and the control group(20 cases) .The trail group was treated with Xinganbao Capsule,8 capsules each time,three times a day.The control group was given Heluo Shugan Tablet,5 pills each time,thrice daily.Six months consisted of one therapeutic course.The liver function,four indicators of serum fibrosis,liver histology,and other items were detected.Results Xinganbao Capsule could reduce serum ALT and AST levels,serum HA,PC-Ⅲ and LN levels(all P<0.05) ,showing statistical difference when compared with before treatment.The HA and LN levels decreased more significantly in the control group when compared with before treatment(P<0.05) .Totally 21 patients(53% of the recruited cases) in the trial group completed the liver biopsy twice.After treated with Xinganbao Capsule,81% patients(17/21) had decreased liver inflammation 1 grade or more,52% patients(11/21) had decreased fibrosis staging one or more,and 33%(7/21) patients had no change in fibrosis.Conclusion Xinganbao Capsule could improve the liver function,reduce liver inflammation,and fight against hepatic fibrosis.